Metformin 1000 mg Oral Tablet

DRUG6 trials

Conditions

Alzheimer Disease DementiaAlzheimer's Disease (AD)Coronary Artery DiseaseDiabetes Mellitus, Type 2MelasmaMetforminMild Cognitive Impairment Due to Alzheimer's DiseaseMitochondria

Phase 2

Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

NCT05298670

German University in CairoMultiple Sclerosis

Start: 2022-02-01End: 2023-03-28Target: 80Updated: 2023-03-20

Phase 3

An Evaluation of Treatments for Sustained Clinical Response (18 Months) in Symptomatic Alzheimer's Disease

RecruitingNCT07724132

University College, LondonAlzheimer's Disease (AD), Alzheimer Disease Dementia, Mild Cognitive Impairment Due to Alzheimer's Disease

Start: 2026-07-24End: 2031-03-01Target: 1200Updated: 2026-07-23

Phase 4

USE THE SYSTEMIC METFORMIN IN MELASMA

NCT03475524

Assiut UniversityMelasma

Start: 2019-04-01End: 2021-08-31Target: 60Updated: 2021-08-03

Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

CompletedNCT03693560

Damanhour UniversityCoronary Artery Disease, Diabetes Mellitus, Type 2

Start: 2018-10-08End: 2019-10-10Updated: 2023-06-13

Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

CompletedNCT04916093

Beni-Suef UniversityDiabetes Mellitus, Type 2

Start: 2019-12-20End: 2020-12-15Updated: 2021-06-07

Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. Metformin Monotherapy

Not yet recruitingNCT07436182

Mansoura UniversityMetformin, Mitochondria

Start: 2026-03-01End: 2026-06-01Target: 176Updated: 2026-02-27

Related Papers

A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial

Frontiers in Immunology2024-02-2123 citations

The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.